Cantor Fitzgerald Reiterates Neutral Rating on Acadia Healthcare (ACHC)

Cantor Fitzgerald analyst Sarah James reiterated a Neutral rating and $40.00 price target on Acadia Healthcare (NASDAQ: ACHC).

The analyst commented, "We are maintaining our $40 price target, which represents a 7.6x EV/EBITDA multiple on our 2026 Adj. EBITDA estimate of $763M, and reflects our uncertainty of when volumes will recover. This is a 34% discount to its historical five-year average, a 1% discount to peer UHS (N), and an 18% discount to the broader provider group high, given its exposure to inpatient psych. The company-listed growth pathways are facility expansion, de novo expansion, JV expansion, M&A, and continuum of care. Risks to our price target include labor cost inflation, achieving a positive spread of pricing to cost inflation, ability to continue heightened growth via expansions, JVs, and M&A that are significantly above historical levels, and the company's ability to grow market share in this highly competitive CTC market."

For an analyst ratings summary and ratings history on Acadia Healthcare click here. For more ratings news on Acadia Healthcare click here.

Shares of Acadia Healthcare closed at $26.94 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Critical One Energy closes second tranche of flow-through placement
• Boeing lands two U.S. defense contracts worth over $711M